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Abstract
DNA is believed to be the primary target for many metal-based drugs. For
example, platinum-based anticancer drugs can form specific lesions on DNA that induce
apoptosis. New platinum drugs can be designed that have novel modes of interaction
with DNA, such as the trinuclear platinum complex BBR3464. Also it is possible to
design inert platinum(IV) pro-drugs which are non-toxic in the dark, but lethal when
irradiated with certain wavelengths of light. This gives rise to novel DNA lesions which
are not as readily repaired as those induced by cisplatin, and provides the basis for a
new type of photoactivated chemotherapy. Finally, newly emerging ruthenium(II)
organometallic complexes not only bind to DNA coordinatively, but also by H-bonding
and hydrophibic interactions triggered by the introduction of extended arene rings into
their versatile structures. Intriguingly osmium (the heavier congener of ruthenium)
reacts differently with DNA but can also give rise to highly cytotoxic organometallic
complexes.
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1. Introduction
The interaction of the anticancer drug cisplatin and its ultimate target, DNA,
has been the subject of extensive research over the last 40 years.
DNA-binding drugs can be classified according to the type of association with
DNA: coordinative binding agents, groove-binders, intercalators, and – most recently
classified[1] – phosphodiester backbone-binders. Non-coordinative interactions rely on
electrostatic interactions, molecular recognition based on shape and size, and hydrogen
bonding. To date, the only DNA-targeted metal-containing drugs in clinical use are
platinum-based drugs, and these are believed to interact with the nucleic acid primarily
through the formation of coordination bonds [2].
Despite the success of cisplatin and platinum-based drugs, the market is still
accessible for new advantageous metal-based drugs that offer better viability, such us
oral administration, which might help to diminish severe side-effects and clinic costs.
Additionally, research is focussed on drugs with higher efficacy, i.e. drugs that interact
differently with the target, DNA, can overcome inherent or acquired cisplatin resistance
in many tumours, and are active towards tumours which are non-responsive to current
chemotherapy.
Some new platinum drugs such as the photoactivatable platinum(IV)
complexes developed in our group combine both advantages [3]. These complexes have
improved aqueous solubility, are active only when irradiated with certain wavelengths
of light and interact with DNA so as to trigger biological processes that eventually lead
to apoptosis in a way which is very different from that of cisplatin [4, 5].
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Ruthenium drugs have achieved in the last decade the status of very promising
candidates for novel cancer therapy, with two drugs already in clinical trials, NAMI-A
and KP1019 [6, 7]. Both these ruthenium(III) complexes are believed to be activated
through reduction to RuII, which opens up a new research field focused on
organometallic ruthenium(II) complexes. These new complexes, and their heavier
congeners, osmium(II) organometallic complexes, offer a more elaborate and intricate
interaction with the double helical DNA, not only forming coordination bonds, but also
H-bonds and intercalation between DNA base pairs [8]. These complexes demonstrate
how transition metals can act as a scaffold for interesting structures that disrupt DNA
normal function and deceive the cellular repair strategy leading to cancer cell death.
From this point of view, it is timely to review the interaction of the above
metal-based complexes with DNA. Most of the drugs reviewed here show non cross-
resistance with cisplatin, an exciting feature which is attributable to the nature of the
interactions with the nucleic acid, the configurations of the adducts that are formed and
the ways in which these differ from those fromed by cisplatin.
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2. Historical background for metal-containing anticancer drugs: cisplatin
and platinated DNA
In the mid-sixties Rosenberg and coworkers discovered serendipitously the
anticancer properties of cisplatin, cis-[PtCl2(NH3)2] (Chart 1), during investigations of
the effect of electric fields on the growth Escherichia coli. They were using platinum
electrodes in a solution containing chloride and ammonium salts among other
constituents, when they observed an unexpected event. The bacteria become long
filaments, and did not replicate. Cell division in the E. coli was thus found to be
inhibited [9]. Further extensive analysis of this unpredicted observation led them to the
conclusion that the bacterial replicative cycle was inhibited by platinum ammine
complexes formed by electrolysis at the platinum electrodes and to the subsequent use
of cis-[PtCl2(NH3)2] as an anticancer drug.
Today, over 30 years after its approval as a chemotherapeutic agent by the
North American Food and Drug Administration in the USA (FDA), cisplatin is still one
of the world’s best selling anticancer drugs. It is responsible for the cure of over 90% of
cases of testicular cancer and it plays an important role in some cancer treatments such
as ovarian, head and neck cancer, bladder cancer, cervical cancer, melanoma, and
lymphomas.
Regardless of the achievements of cisplatin, the drug is efficient in only a
limited range of cancers, and for some other tumours cisplatin might induce acquired
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immunity during the treatment. Also cisplatin can have severe side-effects: often
causing severe nausea and vomiting, bone marrow suppression and kidney toxicity.
Current research on metal complexes is directed partly towards the
development of complexes that kill the types of cancer cells that have an inherently low
response to current chemotherapy, and partly to drugs whose main aim is diminishing
the severe side effects of cisplatin.
Cisplatin mechanism of action
From Rosenberg’s early studies with Escherichia coli it was suspected that
any agent which inhibits cell division should interfere with DNA replication, while the
filamentous growth suggested that RNA and proteins were performing normally. Thus,
already in the 1970’s the implication of DNA in the cytotoxic properties of cisplatin
was well established [10-13], and nuclear DNA has since been thought to be strongly
implicated if not the ultimate target of cisplatin and related metal-based antineoplastic
agents via the process of ligand exchange [2, 14-19].
Prior to DNA attack, cisplatin undergoes aquation. Being a drug able to
hydrolyse, cisplatin will be susceptible to aquation as soon as it enters the body. The
high concentration of chloride ions in blood plasma (ca. 100 mM) preserves its stability
towards hydrolysis [20]. However, the significantly lower intracellular chloride
concentrations inside cellular compartments (ca. 4-23 mM) facilitate rapid (t1/2 ca. 2 h)
hydrolysis of the chloride ligands of cisplatin, leading to activated cationic species
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capable of reacting mono- and bifunctionally. The aquation of cisplatin has been
extensively investigated and reviewed [21-31]. The two hydrolysis steps, to cis-
[PtCl(H2O)(NH3)2]+ and further to cis-[Pt(H2O)2(NH3)2]2+ follow first-order kinetics and
have been investigated in the absence and presence of nucleic acid and oligonucleotides.
Although activated (aquated) cisplatin can interact with various biomolecules
[32], its antitumour activity derives from its capability eventually to form bifunctional
DNA cross-links. The predominant adducts formed by cisplatin with DNA are
bifunctional guanine-guanine (GG) intrastrand cross-links, where the chlorido ligands
have been replaced first by a water molecule through aquation and then by the nitrogen
N7 of adjacent guanine (G) residues [33]. This chelation of DNA triggers a specific
distortion or bending (kinking) of the duplex. This particular platinum-induced kink in
the DNA is considered to be the critical lesion due to the chain of events that the
bimolecular recognition eventually provokes in the cell.
The coordination to N7 of guanines is not surprising as nitrogen N7 atoms of
purines are the most electron-dense and accessible sites in DNA for electrophilic attack
by platinum. They are exposed in the major groove of the double helix, and not
involved in base-pair hydrogen-bonding. The major cisplatin-DNA adducts –
comprising around 90% of all the adducts – both in vitro and in vivo were indeed found
to be: 1,2-intrastrand d(GpG) cross-links (between adjacent guanines) in ca. 50-65%,
and 1,2-intrastrand d(ApG) cross-links in ca. 25%, (between adenine and adjacent
guanine from 5 to 3). In addition, 1,3-intrastrand d(GpNpG) cross-links (intrastrand
adducts between purines separated by one or more intervening bases) were present in
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less than 10%, together with interstrand cross-links, monofunctional adducts to guanine
residues, and DNA-Pt-protein cross-links (see Figure 1) [14, 15, 33-36].
[Figure 1]
The significant prevalence of intrastrand GG cross-links over any other adduct
has been examined in the context of contributions of H-bonding, the electrostatics in the
vicinity of the binding site, and the steric effects of adduct conformation. It has been
argued that hydrogen bonding between the NH3 of the DNA-cisplatin complex and O6
of a nearby guanine – not possible for adenine – has a large impact on the adduct
configuration, being essential for stability and eventual cytotoxic activity [37-39]. The
small size of the NH3 group might also be important [40].
Lippard and coworkers published the first crystal structure of a cis-
{Pt(NH3)2}2+ adduct of cisplatin with a dinucleotide [41]. The nucleobases are in anti
conformation, and the two oxygens O6 atoms are on the same side of the platinum
coordination plane, i.e. head-to-head orientation. The same group published the first
crystal structure of the cisplatin fragment coordinated to a double-stranded
oligonucleotide (a dodecamer), cis-
[Pt(NH3)2{d(CCTCTG6G7TCTCC)d(GGAGACCAGAGG)}] (see Figure 2, left) [42].
They observed rolling of the adjacent guanines towards one another by 49°; however
the overall bend in the duplex could not be quantified. Three years after this crystal
structure, the same group published the NMR structure of the same adduct in solution
[43]. They found similar features, although more pronounced in solution (Figure 2,
right). The rolling of the guanines towards one another was 61° leading to an overall
helix bend angle of 78°. The NMR study also gave the unwinding of the helix at the site
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of platination, which was 25°. Common to both structures is the coordination of the cis-
{Pt(NH3)2}2+ fragment to G6 and G7 with bending of the duplex significantly towards
the major groove without disruption of the Watson-Crick hydrogen bonding. As a
result, the minor groove opposite the platinum adduct is widened and flattened,
affording a geometry with characteristics of A- and B-type DNA.
[Figure 2]
Once cisplatin has reached and attacked DNA, the response of the cell towards
repair of the damage is crucial for the anticancer activity of cisplatin. Cisplatin-DNA
adducts are primarily removed by nucleotide excision repair (NER), which consists of
recognition, incision, excision, repair synthesis and ligation [19]. If this repair
mechanism fails the probability of cancer cell survival decreases.
Why is cisplatin-DNA damage not repaired? Lippard and coworkers have
argued that GG cross-links, which help stabilise an opened and flattened minor groove,
may be an essential structural feature in the recognition and binding of HMG-domain
proteins, leading to “repair shielding” (see Figure 3); the damage persists and ultimately
provokes apoptosis [44-46]. A second hypothesis is that cisplatin-damaged DNA
hijacks HMG-domain proteins and other nuclear proteins away from their natural
binding sites, leading to cellular stress and eventually cell death. These two hypotheses
are not mutually exclusive [47].
[Figure 3]
In recent years a great progress has been made in this area and a number of
proteins have been implicated in Pt-DNA adduct recognition [48, 49]. The TATA-
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binding protein (TBP) binds to cisplatin-modified DNA [50], and appears to have
higher specificity for Pt-damaged DNA than for the TATA box, being therefore
sequestred and inhibiting in vitro transcription [51, 52]. Other proteins, such as p53, can
enhance the sensitivity of the cells to the cisplatin [53], and contribute to increase
protein binding [54].
DNA adduct formation of cisplatin-like drugs
There are other six platinum-based drugs in clinical use today, i.e. cisplatin,
carboplatin, and oxaliplatin (l-OHP) worldwide, and nedaplatin, (254-S), lobaplatin, (D-
19466), and heptaplatin (SKI 2053R) in Japan, China and South Korea, respectively
(see Chart 1).
Carboplatin, for example, was developed in the search for a drug less toxic
than cisplatin. It was thought that a platinum analogue with the same carrier ligands as
cisplatin would form the same DNA lesions, maintaining cisplatin antitumour activity.
In carboplatin, the ligands susceptible to nucleophilic substitution are the oxygen
carboxylates of chelated cyclobutanedicarboxylate. By having less labile ligands, this
analogue reacts with nulceophiles to a lesser extent than cisplatin, and is less toxic.
Thus, it was found that carboplatin, is less toxic than cisplatin, with no significant renal
or neural toxicity, and at the same time is as effective as, or even more active than
cisplatin in some tumours. Due to the presence of the same carrier ligands (NH3),
carboplatin and cisplatin eventually form the same DNA adducts, and the differences
between these two drugs is due to the much slower DNA binding kinetics of carboplatin
[12, 55, 56]. The same scenario is expected for nedaplatin where the carrier ligands are
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also ammonia groups. Thus the principle is established that not only thermodynamic
and structural features are important in the design of metal complexes as drugs, but
kinetic factors are too.
There appear to be few published studies on DNA adducts formed by
lobaplatin or heptaplatin [57, 58]. The case is different for oxaliplatin. Oxaliplatin,
(trans-1R,2R-diaminocyclohexane)oxalato platinum(II), first synthesised by Kidani et
al. in 1978 [59], is the latest worldwide approved platinum-based anticancer agent. It
has shown a broad spectrum of antitumour activity [60] with a partial or a non-cross-
resistance with cisplatin in a wide range of human tumours in vitro and in vivo [60-63].
Oxaliplatin also has similar DNA-binding properties to its congener, leading to the same
type of DNA-Pt cross-links, although the amount of the different types of adduct varies
in comparison to cisplatin. Several studies show that oxaliplatin is less reactive and
forms fewer adducts with cellular DNA than cisplatin. Additionally, there are two
published structures of oligonucleotide-oxaliplatin adducts for two different
dodecamers: a 2.4 Å crystal structure of a 1,2-d(GpG) intrastrand cross-link in a DNA
dodecamer duplex formed by reaction with oxaliplatin [64], and a related NMR solution
structure [65]. The crystal structure is comparable to that of a cisplatin adduct published
by Takahara et al. The sequences of the oligonucleotides used were identical, 5-
d(CCTCTGGTCTCC), and the crystal structures of the two adducts are very similar.
Therefore, the differences in cytotoxic activity of the two platinum complexes are not
readily correlated with these structures. Wu and Chaney have made an attempt to
explain these differences based on the solution structure of a similar dodecamer, with
the sequence 5-d(CCTCAGGCCTCC) [65, 66]. In addition, they reported very recently
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the solution structures of the above DNA dodecamer duplex with and without a cisplatin
1,2-d(GG) intrastrand cross-link, and the detailed comparison with the 1,2-d(GG)
intrastrand cross-link from the reaction of the same oligonucleotide with oxaliplatin. For
example, when comparing average solution structures, the platinum-oligonucleotide
adduct from reaction of the oligonucleotide with oxaliplatin bends the DNA by 31°
(overall bend angle), while the cis-{Pt(NH3)2(GG)} adduct from cisplatin bends the
DNA by 22° [67]. The different response of cellular proteins to these structurally-
different DNA adducts may be responsible for the differences in cytotoxicity, and
spectrum of activity against different tumours for oxaliplatin and cisplatin.
Therefore, the reason why oxaliplatin adducts lead to fatal lesions in cisplatin-
resistant cell lines, and differences in mutagenicity in comparison to cisplatin and
carboplatin, might be explained by the different discrimination of cisplatin and
oxaliplatin adducts by cellular proteins [65].
In the search for new agents which can circumvent resistance, either inherent
or acquired, to cisplatin by many tumours, new drugs are needed that exert their
cytotoxicity through a different mechanism of action, e.g. via new types of DNA-
damage. Trans-platinum complexes and multinuclear-platinum complexes are
promising candidates as they can give rise to unusual DNA-adducts and hence different
activity profiles compared to cisplatin and its analogues.
DNA-damage by platinum complexes with non-cisplatin-like structure
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Complexes based on the square-planar geometry cis-[PtX2(amine)2]
complexes produce very similar types of adduct on target DNA – as exemplified by
cisplatin, carboplatin, and oxaliplatin. It is therefore not surprising that they induce
similar biological responses. This consideration led to the hypothesis that development
of platinum compounds structurally-different from cisplatin may lead to different types
of DNA-Pt adducts, and to a different spectrum of clinical activity, perhaps
complementary to cisplatin.
This is the case for trans-platinum complexes [68-73], and is also the case for
multinuclear platinum complexes.
The most successful of this type of complex so far is [(trans-PtCl(NH3)2)2{-
trans-Pt(NH3)2(NH2(CH2)6NH2)2}]4+, BBR3464 – first reported in 1988 [74] (Chart 2).
It has successfully finished [75] phase I after extensive in vitro and in vivo
investigations [76-82]. As is general for polynuclear platinum compounds, BBR3464
shows rapid binding to DNA with a t1/2 of ca. 40 min probably due to its high charge
and charge-mediated pre-association. The unwinding angle of 14º for supercoiled
plasmid DNA is indicative of bifunctional DNA binding, with ca. 20% of the DNA
adducts being interstrand cross-links, through binding to guanine bases [76]. BBR3464
forms monofunctional adducts with guanine residues that close to 1,4-interstrand cross-
links on the self-complementary DNA 12-mer 5-{d(ATATGTACATAT)2} and
octamer 5-{d(ATGTACAT)2}, with the two platinum atoms coordinated in the major
groove at the N7 positions of guanines that are four base pairs apart on opposite DNA
strands. The central tetraamine linker unit of [trans-
H2N(CH2)6NH2Pt(NH3)2NH2(CH2)6NH2] is located in the minor groove [82, 83].
[Chart 2]
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The most relevant feature of this special DNA binding is the lack of severe
DNA distortions such as a kink, or significant unwinding of the helices, which are
characteristic of DNA adducts of mononuclear platinum complexes. One of the direct
consequences of this mild Pt-induced DNA conformational change is that these adducts
appear to be poor substrates for recognition by proteins, such as those containing the
HMG domain, which bind to rigidly-bent DNA, as found for cisplatin. This might be
due to the central platinum unit lying non-covalently on the minor groove in the place in
which an HMG phenylalanine intercalates in the case of the ternary adduct formed by
HMG and DNA adducts of cisplatin (see Figure 3) [46]. The flexibility of the DNA-Pt
adduct might also confer modest attraction for nucleotide-excision repair proteins.
Therefore, it seems that the recognition by HMG domain proteins of DNA-
BBR3464 adducts is not a crucial step in the mechanism of cytotoxicity of BBR3464, as
claimed for cisplatin. This would support the original hypothesis that polynuclear
platinum compounds coordinating and modifying DNA in a different way than the
mononuclear complex represent a novel class of platinum anticancer drugs acting by a
different mechanism than cisplatin and its analogues.
A comprehensive overview of multi-nuclear platinum drugs has recently been
published by Wheate and Collins [84, 85].
3. Photoactivatable platinum(IV) complexes
The oxidation state of platinum in complexes has a major effect on their
geometry and reactivity. Octahedral platinum(IV) complexes may be advantageous in
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medicinal chemistry because they are less susceptible to substitution reactions and so
undergo fewer reactions on route to the tumour. This results in fewer undesired side-
effects and reduced drug loss due to deactivation compared to square-planar
platinum(II) complexes. In other words they can have reduced toxicity and higher
activity, i.e. a higher therapeutic index. Another advantage of these complexes is their
higher aqueous solubility. Precisely this feature of platinum(IV) complexes has been
exploited by Tobe and coworkers, who selected iproplatin (CHIP, JM9, cis,trans,cis-
[PtCl2(OH)2(isopropylamine)2]) from a range of platinum(IV) complexes for its high
aqueous solubility [86]. Iproplatin entered phase I and II clinical trials [87, 88], and
even phase III [89], but was ultimately found to be less active than cisplatin and so has
not been registered for clinical use [90]. Other complexes such as tetraplatin
([PtCl4(D,L-cyclohexane-1,2-diamine)], also called ormaplatin) [91] and orally
administrable JM216 (satraplatin, cis,trans,cis-[PtCl2(OAc)2(NH3)cyclohexylamine])
[92-94] have also reached clinical trials. More recently, LA-12, an analogue to the latter
with an hydrophobic 1-adamantylamine ligand instead of cyclohexylamine (OC-6-43)-
bis(acetato)adamantylamine(ammine)dichloridoplatinum(IV), has entered clinical phase
I after succesfull pharmacokinetic, in vitro and in vivo studies [95-100].
Despite studies reporting in vitro binding of platinum(IV) species to
nucleobase models in the absence of reductants [101-107], evidence that platinum(IV)
species can enter cells [108], and that they can bind to DNA more slowly but at similar
sites as their platinum(II) counterparts [109-111], it is believed that PtIV is likely to be
reduced before undergoing substitution [112]. Reduction to platinum(II) is probably
essential for activation and effective antitumour activity of platinum(IV) complexes
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[113-118]. Platinum(IV) complexes would not be expected interact with nucleic acids in
vivo due to the slow substitution kinetics compared to their reduction rates since
substitution is slow. For this reason these complexes are often considered to be pro-
drugs.
Controlled activation of platinum(IV) pro-drugs could form the basis of an
effective drug design strategy. In the last few years we have been developing a new
class of platinum complexes, which are inert until photoactivated by certain
wavelengths of light, a procedure which might avoid the severe side-effects of
currently-used platinum drugs.
Because anticancer agents stop replication of rapidly-dividing cells, e.g.
healthy cells of the bone marrow, GI-tract, and skin, these cells are particularly
vulnerable to chemotherapy. Additionally, the therapeutic index (i.e. correlation
between toxic dose and curative dose) of active platinum(II) complexes is relatively
narrow, so cancer cells need only to acquire a low level of resistance to a toxic agent to
unbalance the ratio, and the treatment will eventually fail. In other words, classical
platinum drugs have severe toxicity and the development of resistance can prevent the
success of chemotherapy. There is, therefore, a clinical need to develop anticancer drugs
with significantly reduced toxicity without diminishing efficiency. The groups of
Bednarski and our own are developing new types of anticancer platinum-based drugs
that are strong candidates to satisfy this need.
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Since reduction to PtII appears to be an important step in the mechanism of
action of PtIV anticancer complexes, control of when and where this reduction takes
place, controls the activation of the pro-drug, and hence its toxicity. In general, many
clinically useful antitumour agents are pro-drugs, and indeed their success is due to this
fact. The use of photoactivatable PtIV complexes may allow the activation process to be
controlled in an exquisite fashion and provide a new area for drug development.
Photochemical reduction of PtIV to PtII occurs by complex mechanisms. With
appropriate choice of ligands, hexa-coordinated platinum(IV) photolabile complexes
can be prepared. Then, the light-sensitive PtIV pro-drugs can be photoactivated to
antitumour PtII agents directly at the site of the tumour with laser light.
Desirable features for an ideal photosensitiser include the following. First,
stability under physiological conditions is essential with a plasma half-life long enough
to allow accumulation, but at the same time the elimination time should be sufficiently
rapid to reduce light-toxicity after treatment. Secondly, the longer the wavelength of
activiation, the greater the depth of penetration of the light, especially red and near
infrared light (600-1000 nm, the so-called “phototherapeutic window”). It would also be
convenient if the photosensitiser is oxygen-independent as cancer cells are often
hypoxic. An ideal compound would also have minimal dark toxicity.
Two types of platinum(IV) photoactivatable anticancer complexes have been
reported: diiodo complexes and diazido complexes.
The first photoactivated PtIV anticancer complexes contained iodide as a
reducing ligand with general formula trans,cis-[Pt(X)2I2(en)], where en =
ethylenediamine and X = Cl, OH, acetate, or methylsulfonate [119]. Ethylenediamine, a
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bidentate chelating ligand, was chosen as the non-leaving ligand to avoid
photoisomerizations. The diiodo complexes have intense iodide-to-PtIV ligand-to-metal
charge-transfer (LMCT) bands and are photolabile at ca.  = 400 nm.
Pt-DNA binding modes range from irreversible platination when X = Cl or SO2CH3 (not
affected by light), to no platination over 6 h in the case of X = OH, or to 25%
platination only after light exposure in the case of X = OAc [119]. The results of the
DNA-platination studies were confirmed by NMR studies in which 5-GMP was used as
a model [120]. Moreover, the complexes with X= Cl, OH, or SO2CH3 were found to be
cytotoxic in a human bladder cancer cell line, but the differences between light and dark
toxicities were not as great as had been expected [119].
Thus, the cytotoxicity and DNA binding studies involving irradiation of the
diiodo-PtIV complexes were promising, but these complexes were not suitable as
photoactivated drugs because they are too easily reduced by thiols in and outside of cell,
causing a facile reduction of the diiodo-PtIV complexes to cytotoxic PtII species before
light activation. Nevertheless, these studies showed that the development of
photoactivatable PtIV complexes is feasible.
The diazido complexes developed in our laboratory, however, are stable
enough to reduction and exhibit the main features required for a photoactivated drug:
non-toxicity in the dark and retention of cisplatin-like activity when irradiated.
These azide-PtIV complexes have the general formula [PtIV(N3)2(OH)2(am)2],
where only the hydroxo ligands are maintained trans to one another, and the am(m)ines
can be cis and chelated as e.g. ethylenediamine (Chart 3) or trans. One possible
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mechanism involves electron donation form the azido ligands to PtIV followed by
combination of the azidyl radicals (N3) (Figure 4) to form molecular nitrogen (N2),
preventing reoxidation of the platinum centre. This fast decomposition may contribute
to the efficiency of photoredox reactions involving complexes containing azido ligands.
[Chart 3]
[Figure 4]
The stability in solution and towards potential targets such as the guanine
bases of RNA and DNA in the dark has been investigated by NMR. The cis complexes,
1 and 2 , are stable towards hydrolysis for 90 days, inert to reaction with nucleobases
such as 5’-GMP and d(GpC) in the dark and, most significantly, react only very slowly
with GSH over a period of several weeks [101, 121].
Reactions of the 15N-labelled complexes, 1 and 2, have been followed in
aqueous solution in the presence of 5’-GMP and d(GpG), by 1D 1H, 2D [1H,15N]
HSQC, and 2D [1H,15N] HSQC-TOCSY NMR spectroscopy.
The complexes are cytotoxic toward 5637 human bladder cancer cells under
irradiation. Nucleotide cross-linking induced by photoreactions of 1 and 2 was
observed. The formation of cisplatin-like bifunctional intrastrand GG adducts in a 212-
bp fragment of pSP73KB plasmid and in a 40-mer DNA duplex, has been demonstrated
with light of various wavelengths [101, 121, 122].
The all-trans complex trans,trans,trans-[PtIV(N3)2(OH)2(15NH3)2], 3, has
comparable cytotoxicity to cisplatin towards human HaCaT keratynocites, and lacks
toxicity to cells in the dark. Additionally, it has a much higher aqueous solubility (>20
mM) than the cis isomer 1 and more favourable absorption spectrum, with a LMCT
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band more intense and shifted to longer wavelength, i.e. more penetrating.
Photoreactions and nucleotide interactions have been also investigated in the presence
of 5-GMP by 1D 1H and 2D [1H,15N] HSQC NMR techniques [123], showing stability
in the dark and reaction only upon irradiation.
In summary, the PtIV diazido-complexes 1, 2, and 3 are stable under biological
conditions, but are reduced and bind to nucleotides upon radiation with light of various
wavelengths. They are phototoxic towards several different cell lines, including
cisplatin-resistant cells, while remaining inactive in the dark. So far, investigations into
the mechanism of action of these compounds indicate that they exert their cytotoxic
effect in a different way to cisplatin. This new class of photoactivatable PtIV-azide
complexes has the potential to avoid the side-effects associated with cisplatin, whilst
having the advantage of being oxygen-independent.
Recently, a highly potent complex from this class containing pyridine trans to
ammonia has been synthesised. The complex trans,trans,trans-
[PtIV(N3)2(OH)2(NH3)(pyridine)], 4, was found up to 80 times more cytotoxic than
cisplatin in the ovarian cancer cell line A2780 whilst inactive and stable toward
biological reductants in the dark. It binds to DNA less regularly than cisplatin and
mainly to guanines and cytosines, i.e. like transplatin. It also binds, but to a less extent,
to adenines. Complex 4 was found to form mainly trans azido/guanine, and then trans
diguanine PtII adducts, which are probably mainly intrastrands between two guanines
separated by a third base. It also forms bifunctional interstrand crosslinks with DNA
although the percentage is very low (6%) and their relative efficacy is unknown. This
may suggest that most of the DNA interactions involve intrastrand crosslinks and/or
monofunctional lesions. DNA repair synthesis of these adducts on plasmid DNA was
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found to be markedly lower than that induced by either cisplatin or transplatin. Finally,
data from ethidium fluorescence assays suggest that the damage to the DNA spans more
base pairs around the platinated site than cisplatin [124].
Photoactivation can apparently lead to the formation of platinated DNA
lesions which are not as readily repaired as those formed by conventional PtII anticancer
complexes, especially by trans diam(m)ine complexes [123]. This may lead to novel
mechanisms of action and therefore to clinically useful drugs [3].
4. Ruthenium arene complexes
In the 1970’s Clarke et al. reported pentaammine(purine)ruthenium(III)
complexes capable of inhibiting DNA and protein synthesis in human nasopharyngeal
carcinoma cells in vitro [125], which triggered interest in ruthenium complexes as
potential anticancer pharmaceuticals [126]. During the following decade, Mestroni et al.
developed hexacoordinated RuII complexes with dimethylsulfoxide and chloride
ligands, particularly, cis- and trans-RuCl2(dimethylsulfoxide)4, which exhibit anticancer
activity in vitro and in vivo. The complexes were shown to interact both in vitro and in
vivo with DNA, their most likely target [127].
Today, there are two Ru-based anticancer drugs in clinical trials: NAMI-A,
developed in Trieste by Mestroni, Alessio, and coworkers, and KP1019, developed by
Keppler and coworkers in Vienna (Chart 4).
[Chart 4]
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NAMI-A has a relatively low toxicity towards cancer cells, but is particularly
effective against metastases from solid tumours both in experimental mouse tumours
and against human tumours engrafted in the nude mouse [128-131], being scarcely
effective in solid tumours. The drug has now completed phase I clinical trials [132].
However, in contrast to the other metal-based anticancer drugs reviewed here,
the antimetastatic activity of NAMI-A is thought to be due to the combined effects on
the control of angiogenesis (possibly because it interferes with NO metabolism in vivo)
[131, 133] and anti-invasive properties towards tumour cells and on blood vessels, and
not to its interaction with nucleic acids, although it does interact with DNA in vitro
[129].
There is a number of reviews on the preclinical development of NAMI-A and the
different approaches concerning the mechanisms of action of this type of drug by Sava
et al. [134, 135].
Indazolium trans-[(tetrachloride)bis(1H-indazole)ruthenate(III)] (KP1019 or
FFC14A) exhibited cytotoxic activity against colon carcinomas in rats in preclinical
investigations [136-138]. The preclinical development of KP1019 has been recently
reviewed [7, 139, 140].
Octahedral ruthenium(III) complexes are relatively inert towards ligand
substitution [141]. The reduction of ruthenium(III) to ruthenium(II) as an activation
process prior to DNA binding was first suggested in the late 1970’s by Kelman et al.
[125, 126, 142]. Correlations between the RuIII reduction potential and increased
antiproliferative activity for the colon carcinoma cell line SW480 in the series
Unusual DNA binding modes for metal anticancer complexes
24
[RuIIICl4X2]-, where X is 1H-imidazole, 1H-indazole, or triazole [143-145], confirm this
belief. KP1019 is generally considered a pro-drug, with a reduction potential accessible
to biological reductants [144, 146]. Although it has been suggested that KP1019
undergoes activation in vivo through reduction from RuIII to RuII, and then promotes
interactions with biomolecules after labilization of the RuII-Cl bonds, aquation of the
RuIII-Cl bond has also been investigated [147, 148]. It was found that KP1019
undergoes aquation in aqueous solution in a similar time-scale to that of cisplatin. DNA
has been proposed as one of the biological targets of KP1019, and it has also been
reported that the drug triggers apoptosis [149]. However, the cellular mechanism of the
activation of apoptosis are still under investigation [140, 144, 150].
Recently, we have explored the potential of RuII(arene) complexes [(6-
arene)Ru(X)(Y)(Z)] as antitumour drugs. They possess characteristic “piano-stool”
structures (Chart 5, where X-Y is a neutral chelating ligand, and Z is monoanionic). In
these complexes ruthenium is already in its lower (2+) oxidation state which may be
important for the cytotoxicity of the drug in vivo. The arene ligand, binding as an 6
electron-donor, and a -acceptor, confers stability to the +2 oxidation state. The
presence of a chelating ligand, XY, seems to provide additional stability to the whole
structure. The ligand Z is the “leaving group”, such as a halide, and allows activation of
the molecule: if labile it can provide a coordination site for biomolecules. Small
variations of the arene and the “legs” of the stool afford versatility to the molecule and
the possibility of fine-tuning their pharmacological properties.
[Chart 5]
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In general Ru-arene complexes show promising cytotoxic activity against
human ovarian cancer cell lines, some complexes being as potent as cisplatin and
carboplatin. Some structure/activity relationships have been established [151-154]. As
an example, when the linker is ethylenediamine and the leaving group is chloride, the
cytotoxicity against A2780 human ovarian cancer cells increases with increasing size of
the coordinated arene. However, substitution of chloride by other halides has only a
small effect on the cytotoxicity of ethylenediamine complexes. Additionally,
substitution of the chelating ligand for labile ligands such as other chlorides, acetonitrile
or isonicotinamide, led to less active complexes, perhaps due to inactivation of a too-
reactive complex before reaching the target. Changing the nature of the donors in the
chelating ligand (e.g. from a diamine to an azopyridine, or changing an N to an O
donor) has also been investigated but the structure-activity relationships become more
complicated [153, 155].
Ruthenium(II) complexes often exhibit good solubility in aqueous solution, a
feature of great importance for a convenient administration of potential drugs. Such
activation through hydrolysis of the Ru-Cl bond may be important for the mechanism of
activation of this type of complex, and their chemical behaviour in aqueous media has
been extensively investigated [153, 154, 156-158]. In general, arene ruthenium
complexes that hydrolyse also exhibit cancer cell cytotoxicity, whereas those that do not
undergo little aquation and are not active.
Once the Ru(arene) complex is activated and the aqua species [(6-
(arene)Ru(X)(Y)(OH2)] has been formed (Chart 5), the ruthenium centre is a potential
Unusual DNA binding modes for metal anticancer complexes
26
target for nucleophilic attack by biomolecules. The binding of ruthenium(II) arene
complexes to nucleobases and DNA in particular is of special interest, as this may be
one of the ultimate targets for this type of agent. A number of studies have confirmed
this postulate[157, 159] and have investigated in detail such interactions [83, 151, 152,
154, 160-162].
Reactions of ruthenium arene complexes of formula [(6-
arene)Ru(en)Cl](PF6), where en = ethylenediamine, arene = biphenyl,
dihydroanthracene, tetrahydroanthracene, p-cymene, or benzene (complexes 5, 6, 7, 8
and 9 in Chart 6) and aqua adducts, and guanine, thymine, cytosine, and adenine
derivatives have been investigated [83]. The reactivity of the various binding sites of
nucleobases towards RuII at neutral pH decreases in the order G(N7) > T(N3) > C(N3) >
A(N7), A(N1) (with binding to cytosine being very weak, and almost none to adenine
derivatives). This base selectivity appears to be enhanced by the ethylenediamine NH2
groups, which form hydrogen bonds with exocyclic oxygens (e.g. C6O of G) but are
non-bonding and repulsive towards exocyclic amino groups of the nucleobases (e.g.
C6NH2 of A) (Chart 7). This pattern of selectivity is found for 5′-mononucleotides [83]. 
It also appears that the phosphate group might play a role in the binding of these
complexes to mono-nucleotides, being the initial binding site before transfer of
ruthenium to the base. Reactions with nucleotides appear to proceed via aquation of
[(6-arene)Ru(en)Cl]+ followed by rapid binding to the 5′-phosphate group, and then 
rearrangement to give N7-, N1- or N3-bound products.
[Chart 7]
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Ruthenium arene complexes 5, 6, 7, 8 and 9 have been found to interact with
natural DNA in a cell-free medium [163]. The kinetics of the binding for those with
extended arenes (5, 6 and 7) to natural double-helical CT DNA is about an order of
magnitude faster than that for cisplatin. The p-cymene complex has slower kinetics. The
DNA binding is quantitative in every case and the Ru-DNA adducts are stable.
Transcription mapping experiments have shown that all the complexes bind
preferentially to guanine residues in double helical DNA. For complexes 5, 6 and 7,
with extended -electron systems, in addition to coordination to guanine, non-
coordinative, hydrophobic interactions between the arene ligand and DNA can occur.
These may include arene-base stacking, and arene intercalation, and minor groove
binding, and are thought to contribute to the driving force for the binding of chloro RuII
arene complexes to double-helical DNA [157]. The data obtained from CD and
polarographic analyses of RuII-modified DNA with complexes 5, 6 and 7 demonstrate
that monofunctional adducts of these compounds distort the DNA conformation and that
the distortion has a nondenaturational character as it is for cisplatin [164]. Complex 4
distorts the DNA conformation and thermally destabilises DNA more severely, and
even denaturational changes can occur. The unwinding angles of supercoiled pSP73KB
DNA induced by RuII arene complexes are very similar for 5, 6 and 7, but markedly
smaller for 8. The linear dichroism (LD) data suggest that there might be insertion into
the minor grove, and the displacement of the intercalator ethidium bromide is more
noticeable by 5, 6 and 7 than for the para-cymene-Ru complex [163]. When comparing
complexes 7 and 8, the complexes with tetrahydroanthracene and p-cymene, the lesser
destabilisation of the DNA in the case of complex 7 is attributable to additional
hydrophobic interactions. As an interacalator, the complex can thermodynamically
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stabilise DNA by lengthening and unwinding DNA, increasing the phosphate spacing
along the helix axis. The nature of the arene can also influence the level of repair
synthesis of ruthenium-damaged DNA. When the arene is tetrahydroantracene, the level
of repair by nuclear escision repair proteins (NER) is lower than for p-cymene as arene,
or for cisplatin [159]. This observation provides additional support for a mechanism
underlying antitumour activity of RuII arene compounds different from that of cisplatin.
Additional investigations into new ruthenium organometallic complexes with
extended arenes such as [(6-arene)Ru(en)Cl]+, where the arene is ortho-, meta- or
para-terphenyl also sustain these findings [165].
In order to investigate nucleoside selectivity we synthesised Ru-arene
complexes with an H-bond acceptor O,O-chelating ligand such as acetylacetonate (acac)
in the place of the H-bond donor N,N-chelating ligand such as ethylenediamine (en). If
our hypotheisis was correct these complexes should show inverted selectivity. We
observed that the affinity of acac-type complexes for adenosine (N1- and N7-bound)
can be greater than for guanosine, and there is little binding to cytidine or thymidine
[153, 158].
Due to the success of these complexes as anticancer drug candidates, and
taking into account that they coordinate to DNA only monofunctionally as opposed to
lethal bifunctional cisplatin-DNA adducts, bifunctional Ru-arene analogues were
synthesised [166]. Surprisingly, for the dinuclear complexes [6:1-
C6H5(CH2)nNH2)RuCl2] 1 (n = 3) and 2 (n = 2), both single hydrolysis and binding to
one molecule of the model base 9-ethylguanine is relatively fast, whilst the second
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hydrolysis step and futher reactions with nucleobases is slow and the binding weak. The
unwinding angle induced in negatively supercoiled DNA (9°) is less than that induced
by bifunctional cisplatin binding (13°). It was found that only monofunctional DNA
adducts formed (by interstrand assays and by the Ru-DNA adducts failing to produce
stopsites for pSP73KB plasmid DNA transcription by RNA polymerase). Perhaps less
surprinsing was finding the complexes exhibit little cytotoxicity toward the ovarian
cancer cell line A2780 (IC50 > 100 M) [166].
Since the intracellular tripeptide glutathione (-L-glutamyl-L-cysteinylglycine,
GSH) is present at millimolar concentrations in cells and can inactivate cisplatin,
reactions of RuII-arene complexes with guanine derivatives have been studied in the
presence of excess GSH. These studies have revealed a new mechanism for DNA
ruthenation involving oxidation of coordinated S-bound glutathione to the sulfenate
which weakens the Ru-S bond and allows guanine to coordinate [154].
Recently, Liu et al. have studied the interaction of the monofunctional
fragment {(6-biphenyl)Ru(en)}2+ with the 14-mer
d(ATACATGGTACATA)d(TATG18TACCATGTAT) by HPLC-ESI-MS and 2D
NOESY NMR. Single strands can be ruthenated at specific guanines and purified by
HPLC, but on heating and annealing with the comlementary strand, ruthenium migrates
and ruthenation is found at N7 of every guanine residue of the 14-mer duplex. At one
site (G18), two different conformers were identified by NMR. In one conformer,
intercalation of the arene between G18 and adjacent T is observed. In the second
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conformer, the arene is non-intercalated but stacked on a tilted adjacent thymine, lying
on the surface of the major groove (Figure 5) [161].
[Figure 5]
Some appealing DNA interactions have been found for the dinuclear Ru-arene
complex [{(6-biphenyl)RuCl(en)}2(CH2)6]2+ (10 in Chart 8, en = ethylenediamine)
[157]. Both this binuclear complex and its half unit [(6-biphenyl)RuCl(Et-en)]+ (11 in
Chart 8, where Et-en is CH3CH2(H)NCH2CH2NH2) show a very surprising and
interesting feature. These organometallic complexes have dynamic stereogenic centres
in aqueous solution. Dynamic chiral recognition can play a role in the interaction of the
dinuclear complex with chiral DNA allowing selection of the most favourable
diasteromer for binding. The dinuclear complex 10 induced a large unwinding (31°) of
plasmid DNA, twice that of mononuclear 11 (14°). This value is very high, even
compared to multinuclear platinum complexes [167]. Can it be due to interacalation of
the two pendant phenyl rings? Complex 10 effectively inhibited DNA-directed RNA
synthesis in vitro. This dinuclear complex gave rise to interstrand cross-links on a 213-
bp plasmid fragment with efficiency similar to bifunctional cisplatin, and to 1,3-GG
interstrand and 1,2-GG and 1,3-GTG intrastrand cross-links on site-specifically
ruthenated 20-mers. Complex 10 blocked intercalation of ethidium considerably more
than mononuclear 11, where both the free arene rings and the linker are believed to
contribute. The ruthenium dimer, 10, introduces the concept of induced-fit recognition
of DNA by organometallic ruthenium complexes containing dynamic stereogenic
centres via dynamic epimerization, intercalation, and cross-linking.
5. Osmium arene complexes
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Recently, we have investigated the chemical and biological activity of
analogous half-sandwich osmium arene complexes [168-170]. Osmium, the heavier
congener of ruthenium and a third row transition metal, commonly exhibits slower
kinetics than ruthenium, and is often considered to be relatively inert. However, it is
apparent that it is possible to tune the biochemical reactivity of the OsII-arene
complexes through understanding their aqueous solution chemistry. Thus, active OsII-
arene complexes have been designed [171, 172]. Peacock et al. found that the chelating
ligand plays a major role in the stability, nucleobase binding, and cancer cell toxicity.
They synthesised complexes containing a series of N,O-chelates, and found that the
choice of the type of N- and O-donors is crucial. Stability toward formation of inactive
hydroxo-bridge dimers (which can form at micromolar concentrations under similar
conditions to those in cell culture media) and therefore activity of the osmium
complexes is provided by the more acidic chelating oxygen donors and the introduction
of a -acceptor nitrogen such as pyridine, which reduces the electron density on the
metal lowering the pKa of the coordinated water of the aquo-OsII adduct [171].
DNA binding studies on a series of complexes of the type [(6-
arene)Os(LL)Cl]n+, where arene = biphenyl or p-cymene and LL = ethylenediamine,
picolinate, or oxinate (see Chart 9, complexes 12-15) [173], show that these complexes
all bind and distort polymeric DNA with a rate of binding comparable to that of
cisplatin. These complexes vary in cytotoxicity and the toxicity does not appear to
correlate with the extent of cell uptake. The extent of the interaction with DNA
correlates well with the cytotoxicity of these osmium complexes. They coordinate
mainly to guanine with additional non-coordinative interactions, and only complex 13
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undergoes quantitative reaction with DNA. Osmiated-DNA inhibits RNA synthesis like
cisplatin and the ruthenium analogue of 12 (complex 5 in this review). Surprisingly,
ligation experiments suggest that no DNA bending occurs, which differs from the
behaviour of cisplatin. The unwinding angle induced in supercoiled plasmid DNA by
osmium(II) arene complexes is large (21-27) in comparison to the ruthenium analogues
(7-14) or cisplatin (6 for monofunctional and 13 for bifunctional adducts). For
complexes 12, 13 and 14 this may arise from intercalation of the arene interacts into the
duplex. Complexes 12 and 13, with extended electron-rich -systems, can displace the
intercalator ethidium bromide from DNA, so supporting this hypothesis.
5. Conclusions and perspectives
The introduction of platinum drugs into the clinic for cancer treatment has
been very successful and their mechanism of action is known to involve attack on DNA.
Structural distortions of DNA induced by platination are important to protein
recognition and the downstream events which lead to apoptosis and cell death. Hence
there is current focus on the design of new agents which can induce different DNA
structural distortions compared to cisplatin. These new agents may then be effective in
cases where cisplatin is not and also circumvent cisplatin acquired resistance. Recent
developments include di-nuclear and tri-nuclear platinum complexes which can cross-
link distant sites on DNA, and trans complexes. Photoactivatable diazido platinum(IV)
complexes appear to produce lesions of DNA which are more difficult to repair than
those produced by cisplatin and provide the basis for a novel form of
photochemotherapy.
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Organometallic ruthenium(II) monoarene complexes appear to be non-cross-
resistant with cisplatin and can also distort DNA despite being only monofunctional.
DNA base-selectivity can be achieved by coordination of ruthenium to N7 of G, H-
bonding between an amine such as ethylenediamine chelated to RuII and the C6O of G,
as well as intercalation of the arene if it has an extended structure (e.g. biphenyl or an
anthracene derivative). Intriguingly cytotoxic osmium(II) arene complexes appear to
induce significant unwinding of double-helical DNA but cause little bending, in contrast
to ruthenium analogues and to cisplatin. Further work is necessary to understand the
subtleties of such DNA interactions and to optimise the design of osmium arene
complexes for activity.
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CAPTIONS TO FIGURES
Figure 1. Different types of DNA-cisplatin adducts for a given random sequence. The
1,2-intrastrand GG (top left) is believed to be the critical lesion. Y = H2O/OH, Cl,
protein.
Figure 2. X-ray structure [42] (left) and NMR solution structure [43] (right) of the
adduct formed by interaction of cisplatin and the 12-mer
d(CCTCTGGTCTCC)d(GGAGACCAGAGG). Pt, pink; N, deep blue; O, red; P,
orange; C, grey. (PDB: 1AIO and 1A84, respectively).
Figure 3. Adduct formed between the nonsequence-specific domain A of HMG1 and
cisplatin-modified DNA. Pt, pink; N, deep blue; O, red; P, orange; C, grey. HMG is a
purple ribbon with a intercalating phenylalanine highlighted in yellow. (Coordinates
taken from the Protein Data Bank, 1CKT) [46].
Figure 4. Possible mechanism for the photoreduction of a PtIV-diazido complex.
Figure 5. Molecular models of two conformers of duplex dodecamer
d(ATACATGGTACATA)d(TATG18TACCATGTAT) ruthenated at N7 of G18 with
monofunctional fragment {(6-biphenyl)Ru(en)}2+. (A) showing the intercalation of the
arene between G18 and T17. (B) in which the arene is non-intercalated but stacked on a
tilted T17. Color code: en, dark blue;, biphenyl, green; ruthenium, purple (Adapted from
ref. 161).
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